Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Lyra Therapeutics Inc LYRA

Healthcare Biotechnology
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s product candidates include LYR-210, an anti... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:LYRA)

Lyra Therapeutics Provides Corporate Update

GlobeNewswire January 12, 2026

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2025

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

GlobeNewswire October 6, 2025

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire August 12, 2025

Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

GlobeNewswire June 27, 2025

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

GlobeNewswire June 2, 2025

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

GlobeNewswire May 7, 2025

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire May 6, 2025

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire March 13, 2025
View More News ››

Opinion & Analysis (NDAQ:LYRA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:LYRA)

Sell buddy sell.

Otherwise you guys out there will be losing your shorts with this stock today anyway
coolfooldumbguy - January 12, 2026

Buy buddy buy because it's taking off this morning.

It is signalling a big upswing for shareholders of this stock today
coolfooldumbguy - June 2, 2025
View more Bullboard ››

Pelangio Exploration Inc.

Pelangio Exploration Inc.

Pelangio Exploration Inc., a mineral exploration company, engages in the acquisition, exploration, and development of mineral ...
View More »

Podcasts